Consensus Report of the Third International Forum for Liver Magnetic Resonance Imaging
Authors:
- Luigi GrazioliLuigi Grazioli
- Jeong Min LeeJeong Min Lee
- Peter MalfertheinerPMPeter Malfertheiner
- Christoph J. ZechCZChristoph J. Zech
- Lennart BlomqvistLBLennart Blomqvist
- Elmar M. MerkleEMElmar M. Merkle
- 1 December 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 45, S1-S10
Abstract
This consensus report arises from the discussions at the Third International Forum for Liver Magnetic Resonance Imaging, at which attendees evaluated the use of the hepatocyte-specific contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA, Primovist, Bayer Schering Pharma, Berlin, Germany; Eovist, Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ; EOB-Primovist, Bayer Schering Pharma, Osaka, Japan). The impact of Gd-EOB-DTPA uptake by hepatocytes on the enhancement pattern, compared with dynamic imaging with extracellular contrast media, and its value in diagnostic confidence were discussed. Although the dynamic-phase images of typical cavernous hemangiomas are comparable using Gd-EOB-DTPA and gadolinium-based extracellular contrast media, such lesions appear hypointense during the hepatobiliary phase with Gd-EOB-DTPA. The rapid uptake of Gd-EOB-DTPA by hepatocytes results in lesions of hepatocellular origin already appearing hyperintense during the late-dynamic-phase imaging. Focal nodular hyperplasia can be detected with confidence using Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI). Currently, information on the appearance of the Gd-EOB-DTPA-enhanced images of hepatic adenomas in the hepatobiliary phase is limited. Published data support the use of Gd-EOB-DTPA-enhanced MRI for diagnosis of liver metastases. However, some diagnostic algorithms do not address recent advances in imaging technology and fail to recognize the role of Gd-EOB-DTPA in the detection of hepatocellular carcinoma and its ability to distinguish between benign and malignant lesions. Beyond its approved use for the detection and characterization of liver lesions in adults with known or suspected focal liver disease, Gd-EOB-DTPA has the potential to be used in the assessment of liver function and the examination of the biliary system.Keywords
This publication has 95 references indexed in Scilit:
- Improved Characterization of Focal Liver Lesions With Liver-Specific Gadoxetic Acid Disodium-Enhanced Magnetic Resonance ImagingJournal of Computer Assisted Tomography, 2010
- Detection and characterization of focal hepatic tumors: A comparison of T2‐weighted MR images before and after the administration of gadoxectic acidJournal of Magnetic Resonance Imaging, 2009
- Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinomaJournal of Gastroenterology, 2009
- Receiver Operating Characteristic Analysis of Diffusion-Weighted Magnetic Resonance Imaging in Differentiating Hepatic Hemangioma From Other Hypervascular Liver LesionsJournal of Computer Assisted Tomography, 2008
- Hepatocellular adenoma: what is new in 2008Hepatology International, 2008
- Contrast agents for hepatic MRICancer Imaging, 2007
- Imaging of liver metastases: MRICancer Imaging, 2007
- Nonoperative imaging techniques in suspected biliary tract obstructionHPB, 2006
- Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liverHepatology, 1997
- The SGOT/SGPT ratio?An indicator of alcoholic liver diseaseDigestive Diseases and Sciences, 1979